Patient Enrollment Expanded for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM as UVA Cancer Center Doses First Patient December 4, 2024
First patient dosed in Ph 3 trial HLX22-GC-301 of HLX22 in combination with trastuzumab and chemo in 1L HER2+ve advanced G/GEJ cancer patients November 26, 2024
First Patient Dosed in Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies November 26, 2024
Enrollment of 68 patients completed in Ph 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule November 26, 2024
TUSCANY Ph 1/2 Study for Newly Diagnosed AML Patients Initiated to Receive Tuspetinib-based Triplet Therapy November 26, 2024
First Patient Enrolled in Ph 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors November 26, 2024
First Patient dosed in Ph 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers November 26, 2024
SRN-101 announced as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA November 26, 2024
ALISCA-Breast1 Ph 2 Trial of Alisertib initiated in HR+ve, HER2-Negative Metastatic Breast Cancer November 26, 2024
Promising Preliminary Results of Investigator-Initiated Ph 1 Trial of Keytruda and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors Announced November 19, 2024
Planned Unblinded Data Readout for MIRACLE Ph 3 R/R AML Pivotal Trial Accelerated to H2 2025 November 19, 2024
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 November 13, 2024
First patient dosed in Ph 1/2 study of Silmitasertib in children and young adults with R/R solid tumors November 12, 2024
Positive TNG462 Clinical Data reported and Update provided on PRMT5 Development Program November 12, 2024
Ph 3 Trial of Adjuvant V940 (mRNA-4157) + KEYTRUDA After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of NSCLC Initiated November 5, 2024
Ph 2 Study of Masofaniten + Enzalutamide in metastatic CRPC Patients terminated; efficacy signals observed will not achieve target product profile November 5, 2024
First Patient Dosed in Ph 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers November 5, 2024
AKIR001 cleared to start Ph 1 clinical trial in multiple cancer types, including anaplastic and iodine-refractory thyroid cancer, SCCHN, and NSCLC November 5, 2024
